Integration of retroviral vectors

Current Opinion in Immunology

Volumn 24, Issue 5, 2012, Pages 592-597

  Gabriel, Richard ^a   Schmidt, Manfred ^a   von Kalle, Christof ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; INTEGRASE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; VIRUS DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CPG ISLAND; ENZYME STRUCTURE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC TRANSDUCTION; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MALIGNANT TRANSFORMATION; NONHUMAN; PATIENT SAFETY; POLYMERASE CHAIN REACTION; REVIEW; RISK BENEFIT ANALYSIS; RNA SPLICING; SPUMA VIRUS; TRANSCRIPTION INITIATION SITE; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; DNA, VIRAL; GENE PRODUCTS, POL; GENETIC LOCI; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PROVIRUSES; RETROVIRIDAE; VIRUS INTEGRATION;

EID: 84867746831     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.08.006     Document Type: Review

References (62)

1. Nowotny M. Retroviral integrase superfamily: the structural perspective. EMBO Rep 2009, 10:144-151.
2. Delelis O., Carayon K., Saib A., Deprez E., Mouscadet J.F. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008, 5:114.
3. Schmidt M., Schwarzwaelder K., Bartholomae C., Zaoui K., Ball C., Pilz I., Braun S., Glimm H., von Kalle C. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007, 4:1051-1057.
4. Mueller P.R., Wold B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 1989, 246:780-786.
5. Pfeifer G.P., Steigerwald S.D., Mueller P.R., Wold B., Riggs A.D. Genomic sequencing and methylation analysis by ligation mediated PCR. Science 1989, 246:810-813.
6. Gabriel R., Eckenberg R., Paruzynski A., Bartholomae C.C., Nowrouzi A., Arens A., Howe S.J., Recchia A., Cattoglio C., Wang W., et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009, 15:1431-1436.
7. Paruzynski A., Arens A., Gabriel R., Bartholomae C.C., Scholz S., Wang W., Wolf S., Glimm H., Schmidt M., von Kalle C. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protocols 2010, 5:1379-1395.
8. Brady T., Roth S.L., Malani N., Wang G.P., Berry C.C., Leboulch P., Hacein-Bey-Abina S., Cavazzana-Calvo M., Papapetrou E.P., Sadelain M., et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res 2011, 39:e72.
9. Gillet N.A., Malani N., Melamed A., Gormley N., Carter R., Bentley D., Berry C., Bushman F.D., Taylor G.P., Bangham C.R. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 2011, 117:3113-3122.
10. Arens A., Appelt J.U., Bartholomae C.C., Gabriel R., Paruzynski A., Gustafson D., Cartier N., Aubourg P., Deichmann A., Glimm H., et al. Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites. Hum Gene Ther Methods 2012, 23:111-118.
11. Hawkins T.B., Dantzer J., Peters B., Dinauer M., Mockaitis K., Mooney S., Cornetta K. Identifying viral integration sites using SeqMap 2.0. Bioinformatics 2011, 27:720-722.
12. Abel U., Deichmann A., Nowrouzi A., Gabriel R., Bartholomae C.C., Glimm H., von Kalle C., Schmidt M. Analyzing the number of common integration sites of viral vectors-new methods and computer programs. PLoS One 2011, 6:e24247.
13. Presson A.P., Kim N., Xiaofei Y., Chen I.S., Kim S. Methodology and software to detect viral integration site hot-spots. BMC Bioinformatics 2011, 12:367.
14. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
15. Maertens G.N., Hare S., Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010, 468:326-329.
16. Krishnan L., Li X., Naraharisetty H.L., Hare S., Cherepanov P., Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 2010, 107:15910-15915.
17. Lim K.I., Klimczak R., Yu J.H., Schaffer D.V. Specific insertions of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties. Proc Natl Acad Sci U S A 2010, 107:12475-12480.
18. Engelman A., Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012, 10:279-290.
19. Yan N., O'Day E., Wheeler L.A., Engelman A., Lieberman J. HIV DNA is heavily uracilated, which protects it from autointegration. Proc Natl Acad Sci U S A 2011, 108:9244-9249.
20. Brin E., Leis J. HIV-1 integrase interaction with U3 and U5 terminal sequences in vitro defined using substrates with random sequences. J Biol Chem 2002, 277:18357-18364.
21. Holman A.G., Coffin J.M. Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc Natl Acad Sci U S A 2005, 102:6103-6107.
22. Wu X., Li Y., Crise B., Burgess S.M., Munroe D.J. Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J Virol 2005, 79:5211-5214.
23. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
24. Lewinski M.K., Yamashita M., Emerman M., Ciuffi A., Marshall H., Crawford G., Collins F., Shinn P., Leipzig J., Hannenhalli S., et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006, 2:e60.
25. Mitchell R.S., Beitzel B.F., Schroder A.R., Shinn P., Chen H., Berry C.C., Ecker J.R., Bushman F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004, 2:E234.
26. Schroeder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110:521-529.
27. Biffi A., Bartolomae C.C., Cesana D., Cartier N., Aubourg P., Ranzani M., Cesani M., Benedicenti F., Plati T., Rubagotti E., et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011, 117:5332-5339.
28. Suerth J.D., Maetzig T., Brugman M.H., Heinz N., Appelt J.U., Kaufmann K.B., Schmidt M., Grez M., Modlich U., Baum C., et al. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther 2012, 20:1022-1032.
29. Nowrouzi A., Dittrich M., Klanke C., Heinkelein M., Rammling M., Dandekar T., von Kalle C., Rethwilm A. Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol 2006, 87:1339-1347.
30. Trobridge G.D., Miller D.G., Jacobs M.A., Allen J.M., Kiem H.P., Kaul R., Russell D.W. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A 2006, 103:1498-1503.
31. Felice B., Cattoglio C., Cittaro D., Testa A., Miccio A., Ferrari G., Luzi L., Recchia A., Mavilio F. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One 2009, 4:e4571.
32. Ambrosi A., Glad I.K., Pellin D., Cattoglio C., Mavilio F., Di Serio C., Frigessi A. Estimated comparative integration hotspots identify different behaviors of retroviral gene transfer vectors. PLoS Comput Biol 2011, 7:e1002292.
33. Bartholomae C.C., Arens A., Balaggan K.S., Yanez-Munoz R.J., Montini E., Howe S.J., Paruzynski A., Korn B., Appelt J.U., Macneil A., et al. Lentiviral vector integration profiles differ in rodent postmitotic tissues. Mol Ther 2011, 19:703-710.
34. Brady T., Agosto L.M., Malani N., Berry C.C., O'Doherty U., Bushman F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009, 23:1461-1471.
35. Biasco L., Ambrosi A., Pellin D., Bartholomae C., Brigida I., Roncarolo M.G., Di Serio C., von Kalle C., Schmidt M., Aiuti A. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med 2011, 3:89-101.
36. Llano M., Vanegas M., Fregoso O., Saenz D., Chung S., Peretz M., Poeschla E.M. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol 2004, 78:9524-9537.
37. Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., Bushman F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005, 11:1287-1289.
38. Gijsbers R., Ronen K., Vets S., Malani N., De Rijck J., McNeely M., Bushman F.D., Debyser Z. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 2010, 18:552-560.
39. Silvers R.M., Smith J.A., Schowalter M., Litwin S., Liang Z., Geary K., Daniel R. Modification of integration site preferences of an HIV-1-based vector by expression of a novel synthetic protein. Hum Gene Ther 2010, 21:337-349.
40. Ferris A.L., Wu X., Hughes C.M., Stewart C., Smith S.J., Milne T.A., Wang G.G., Shun M.C., Allis C.D., Engelman A., et al. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc Natl Acad Sci U S A 2010, 107:3135-3140.
41. Ocwieja K.E., Brady T.L., Ronen K., Huegel A., Roth S.L., Schaller T., James L.C., Towers G.J., Young J.A., Chanda S.K., et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog 2011, 7:e1001313.
42. Akagi K., Suzuki T., Stephens R.M., Jenkins N.A., Copeland N.G. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004, 32:D523-D527.
43. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
44. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
45. Avedillo Diez I., Zychlinski D., Coci E.G., Galla M., Modlich U., Dewey R.A., Schwarzer A., Maetzig T., Mpofu N., Jaeckel E., et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 2011, 8:1525-1537.
46. Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., Schmidt M., Kramer A., Schwable J., Glimm H., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
47. Kang E.M., Choi U., Theobald N., Linton G., Long Priel D.A., Kuhns D., Malech H.L. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115:783-791.
48. Gaspar H.B., Cooray S., Gilmour K.C., Parsley K.L., Zhang F., Adams S., Bjorkegren E., Bayford J., Brown L., Davies E.G., et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011, 3:97ra80.
49. Ferrua F., Brigida I., Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol 2010, 10:551-556.
50. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
51. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., Down J., Denaro M., Brady T., Westerman K., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
52. Cesana D., Sgualdino J., Rudilosso L., Merella S., Naldini L., Montini E. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 2012, 122:1667-1676.
53. Moiani A., Paleari Y., Sartori D., Mezzadra R., Miccio A., Cattoglio C., Cocchiarella F., Lidonnici M.R., Ferrari G., Mavilio F. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012, 122:1653-1666.
54. Heckl D., Schwarzer A., Haemmerle R., Steinemann D., Rudolph C., Skawran B., Knoess S., Krause J., Li Z., Schlegelberger B., et al. Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther 2012.
55. Nagel J., Gross B., Meggendorfer M., Preiss C., Grez M., Brack-Werner R., Dietzel S. Stably integrated and expressed retroviral sequences can influence nuclear location and chromatin condensation of the integration locus. Chromosoma 2012, 121:353-367.
56. Yanez-Munoz R.J., Balaggan K.S., MacNeil A., Howe S.J., Schmidt M., Smith A.J., Buch P., MacLaren R.E., Anderson P.N., Barker S.E., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12:348-353.
57. Hutson T.H., Foster E., Dawes J.M., Hindges R., Yanez-Munoz R.J., Moon L.D. Lentiviral vectors encoding shRNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in CNS neurons. J Gene Med 2012, 14:299-315.
58. Gabriel R., Lombardo A., Arens A., Miller J.C., Genovese P., Kaeppel C., Nowrouzi A., Bartholomae C.C., Wang J., Friedman G., et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 2011, 29:816-823.
59. Lombardo A., Genovese P., Beausejour C.M., Colleoni S., Lee Y.L., Kim K.A., Ando D., Urnov F.D., Galli C., Gregory P.D., et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007, 25:1298-1306.
60. Staunstrup N.H., Moldt B., Mates L., Villesen P., Jakobsen M., Ivics Z., Izsvak Z., Mikkelsen J.G. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009, 17:1205-1214.
61. Vink C.A., Gaspar H.B., Gabriel R., Schmidt M., McIvor R.S., Thrasher A.J., Qasim W. Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 2009, 17:1197-1204.
62. Matrai J., Cantore A., Bartholomae C.C., Annoni A., Wang W., Acosta-Sanchez A., Samara-Kuko E., De Waele L., Ma L., Genovese P., et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 2011, 53:1696-1707.